Previous 10 | Next 10 |
MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its ...
2024-05-02 16:00:35 ET Summary Annovis Bio's pipeline features a single therapeutic drug, Buntanetap, unlikely to showcase efficacy in AD or PD. Topline data of AD phase II/III trial was released in a press release, and featured a small post-hoc sub-population. The stock plumm...
2024-05-02 09:52:32 ET Summary Annovis Bio, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for neurodegenerative diseases like Alzheimer's and Parkinson's. Their pipeline includes Buntanetap/ANVS 402 for AD, PD, and Lewy Body Dementia, as well as ...
2024-05-02 00:19:50 ET Summary Annovis reported topline data from a Phase 2/3 trial in Alzheimer's disease, but the trial was a failure. The exclusion of 37% of the patient population and the focus on mild AD patients were not pre-specified, raising concerns. Annovis faces fin...
2024-04-30 13:43:00 ET More on mid-day movers & stocks. Bakkt Holdings, Inc. (BKKT) Q4 2023 Earnings Call Transcript Bakkt Holdings, Inc. 2023 Q4 - Results - Earnings Call Presentation Cemtrex, Inc. (CETX) Q1 2024 Earnings Call Transcript Bakkt announces ...
2024-04-30 10:01:07 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 19 out...
A look at the top 10 most actives in the United States Next.e.GO N.V. (EGOX) rose 38.0% to $0.0381 on volume of 59,468,925 shares Greenwave Technology Solutions Inc. (GWAV) rose 1.5% to $0.066 on volume of 45,683,331 shares Global Mofy Metaverse Limited (GMM) rose 68.4% to $1.5667 on volu...
2024-04-30 09:00:04 ET Sumant Kulkarni from Canaccord Genuity issued a price target of $26.00 for ANVS on 2024-04-30 07:34:00. The adjusted price target was set to $26.00. At the time of the announcement, ANVS was trading at $7.28. ANVS currently trades -67.60% versus it...
2024-04-30 08:24:49 ET More on pre-market losers & stocks. Biodexa shares rally 126% on rapamycin licensing deal NewGenIvf signs non-binding term sheet for potential reverse merger with European Wellness Investment Holdings Seeking Alpha’s Quant Rating on ...
2024-04-30 04:49:23 ET Summary On Monday, April 29, Annovis Bio announced their phase 2/3 Alzheimer's Disease trial results, causing stock to drop ~60%. Of the five pre-specified efficacy endpoints, only ADAS-Cog11 results were reported in some details, and only from ~28% of the c...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 86.1% to $0.514 on volume of 587,366,807 shares NVIDIA Corporation (NVDA) fell 1.3% to $122.67 on volume of 214,038,378 shares Tesla Inc. (TSLA) rose 10.2% to $231.26 on volume of 201,850,947 ...
Annovis Bio (NYSE: ANVS) , a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting new data from its phase 3 PD s...
Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Parkinson’s patients with substantial cognitive decline exhibited a very pronounced improvement. Buntanetap showed statistical improvement in the ...